UFF
KRYS icon

USA Financial Formulas’s Krystal Biotech KRYS Stock Holding History

USA Financial Formulas’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$100K Buy
269
+98
+57% +$29.3K 0.02% 179
2026
Q1 		$44.2K Buy
+171
New +$45.5K 0.01% 231

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

USA Financial Formulas's KRYS Position: Q2 2026 in Review

USA Financial Formulas increased its Krystal Biotech (KRYS) stake by 57% in Q2 2026, buying an estimated $29.3K and bringing the position to 269 shares worth $100K. The position accounts for 0.02% of the portfolio, ranked #179.

USA Financial Formulas first reported a position in KRYS in Q1 2026 and has held it in 2 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • USA Financial Formulas held 269 shares of Krystal Biotech worth $100K as of Q2 2026.
  • USA Financial Formulas bought 98 Krystal Biotech shares in Q2 2026, an estimated $29.3K.
  • Krystal Biotech made up 0.02% of USA Financial Formulas's portfolio in Q2 2026, its #179 holding.
  • USA Financial Formulas first reported a position in Krystal Biotech in Q1 2026 and has held it in 2 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on USA Financial Formulas's 13F filing for Q2 2026, filed 4 Aug 2026.